Expert Rev Mol Diagn. 2012;12(3):253-264. WGS offers improved resolution over SNP arrays for detecting CNAs in the genomes of MDS and AML samples. However, it remains critical to use paired normal ...
Myelodysplastic syndrome (MDS) refers to a group of blood cancers that cause your body to make abnormal blood cells. These cells can crowd out normal ones, leaving you with low blood cell counts.
Myelodysplastic syndromes (MDS), also known as myelodysplastic neoplasms, are conditions that can occur when the blood-forming cells in the bone marrow become abnormal, resulting in the marrow not making enough healthy new blood cells.
Myelodysplastic syndrome (MDS) is a type of cancer in which the bone marrow does not produce healthy cells. Find out here about the outlook and life expectancy for a person with MDS.
Many individuals with myelodysplastic syndrome (MDS) have no noticeable symptoms when diagnosed. The condition is often first found after blood testing shows low blood cell counts. Anemia, caused by a lack of red blood cells, is the most common symptom in MDS.
The Minimum Data Set (MDS) is a powerful tool for implementing standardized assessment and for facilitating care management in nursing homes (NHs) and non-critical access hospital swing beds (non-CAH SBs). Its content has implications for residents, families, providers, researchers, advocates, stakeholders, and policymakers, all of whom had expressed concerns about the reliability, validity ...
Minimum Data Set (MDS) 3.0 for Nursing Homes and Swing Bed Providers
The myelodysplastic syndromes (MDS) are group of clonal hematopoietic stem cell abnormalities typified by peripheral cytopenia, dysplastic hematopoietic progenitors, a hypercellular or hypocellular bone marrow, and a high risk of conversion to acute myeloid leukemia.